

Chronic Steatohepatitis (NASH)-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/O4D8257C34CEN.html>

Date: December 2017

Pages: 155

Price: US\$ 3,680.00 (Single User License)

ID: O4D8257C34CEN

Abstracts

Report Summary

Chronic Steatohepatitis (NASH)-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Chronic Steatohepatitis (NASH) industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Chronic Steatohepatitis (NASH) 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Chronic Steatohepatitis (NASH) worldwide and market share by regions, with company and product introduction, position in the Chronic Steatohepatitis (NASH) market

Market status and development trend of Chronic Steatohepatitis (NASH) by types and applications

Cost and profit status of Chronic Steatohepatitis (NASH), and marketing status

Market growth drivers and challenges

The report segments the global Chronic Steatohepatitis (NASH) market as:

Global Chronic Steatohepatitis (NASH) Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa

Global cholic Steatohepatitis (NASH) Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Weight Loss Treatment
Insulin-Sensitizing Agents
Lipid-Lowering Drugs
Antioxidants
Other Agents

Global cholic Steatohepatitis (NASH) Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Clinics
Drug Store
Research institute
Others

Global cholic Steatohepatitis (NASH) Market: Manufacturers Segment Analysis (Company and Product introduction, cholic Steatohepatitis (NASH) Sales Volume, Revenue, Price and Gross Margin):

Boehringer Ingelheim
Cerenis Therapeutics
Connexios Life Sciences
Genfit
Islet Sciences
Nimbus Therapeutics
Verva Pharmaceuticals
Viking Therapeutics
Astazeneca Plc
Galmed Pharmaceuticals Ltd.
GENFIT SA
Gilead Science
Novo Nordisk

Immuron Ltd
Intercepts Pharmaceuticals
Enzo Biochem, Inc
Tobira Therapeutics, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF OHOLIC STEATOHEPATITIS (NASH)

- 1.1 Definition of oholic Steatohepatitis (NASH) in This Report
- 1.2 Commercial Types of oholic Steatohepatitis (NASH)
 - 1.2.1 Weight Loss Treatment
 - 1.2.2 Insulin-Sensitizing Agents
 - 1.2.3 Lipid-Lowering Drugs
 - 1.2.4 Antioxidants
 - 1.2.5 Other Agents
- 1.3 Downstream Application of oholic Steatohepatitis (NASH)
 - 1.3.1 Hospital
 - 1.3.2 Clinics
 - 1.3.3 Drug Store
 - 1.3.4 Research institute
 - 1.3.5 Others
- 1.4 Development History of oholic Steatohepatitis (NASH)
- 1.5 Market Status and Trend of oholic Steatohepatitis (NASH) 2013-2023
 - 1.5.1 Global oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023
 - 1.5.2 Regional oholic Steatohepatitis (NASH) Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of oholic Steatohepatitis (NASH) 2013-2017
- 2.2 Sales Market of oholic Steatohepatitis (NASH) by Regions
 - 2.2.1 Sales Volume of oholic Steatohepatitis (NASH) by Regions
 - 2.2.2 Sales Value of oholic Steatohepatitis (NASH) by Regions
- 2.3 Production Market of oholic Steatohepatitis (NASH) by Regions
- 2.4 Global Market Forecast of oholic Steatohepatitis (NASH) 2018-2023
 - 2.4.1 Global Market Forecast of oholic Steatohepatitis (NASH) 2018-2023
 - 2.4.2 Market Forecast of oholic Steatohepatitis (NASH) by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of oholic Steatohepatitis (NASH) by Types
- 3.2 Sales Value of oholic Steatohepatitis (NASH) by Types
- 3.3 Market Forecast of oholic Steatohepatitis (NASH) by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of oholic Steatohepatitis (NASH) by Downstream Industry
- 4.2 Global Market Forecast of oholic Steatohepatitis (NASH) by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America oholic Steatohepatitis (NASH) Market Status by Countries
 - 5.1.1 North America oholic Steatohepatitis (NASH) Sales by Countries (2013-2017)
 - 5.1.2 North America oholic Steatohepatitis (NASH) Revenue by Countries (2013-2017)
 - 5.1.3 United States oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 5.1.4 Canada oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 5.1.5 Mexico oholic Steatohepatitis (NASH) Market Status (2013-2017)
- 5.2 North America oholic Steatohepatitis (NASH) Market Status by Manufacturers
- 5.3 North America oholic Steatohepatitis (NASH) Market Status by Type (2013-2017)
 - 5.3.1 North America oholic Steatohepatitis (NASH) Sales by Type (2013-2017)
 - 5.3.2 North America oholic Steatohepatitis (NASH) Revenue by Type (2013-2017)
- 5.4 North America oholic Steatohepatitis (NASH) Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe oholic Steatohepatitis (NASH) Market Status by Countries
 - 6.1.1 Europe oholic Steatohepatitis (NASH) Sales by Countries (2013-2017)
 - 6.1.2 Europe oholic Steatohepatitis (NASH) Revenue by Countries (2013-2017)
 - 6.1.3 Germany oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 6.1.4 UK oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 6.1.5 France oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 6.1.6 Italy oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 6.1.7 Russia oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 6.1.8 Spain oholic Steatohepatitis (NASH) Market Status (2013-2017)
 - 6.1.9 Benelux oholic Steatohepatitis (NASH) Market Status (2013-2017)
- 6.2 Europe oholic Steatohepatitis (NASH) Market Status by Manufacturers
- 6.3 Europe oholic Steatohepatitis (NASH) Market Status by Type (2013-2017)
 - 6.3.1 Europe oholic Steatohepatitis (NASH) Sales by Type (2013-2017)
 - 6.3.2 Europe oholic Steatohepatitis (NASH) Revenue by Type (2013-2017)

6.4 Europe oholic Steatohepatitis (NASH) Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

7.1 Asia Pacific oholic Steatohepatitis (NASH) Market Status by Countries

7.1.1 Asia Pacific oholic Steatohepatitis (NASH) Sales by Countries (2013-2017)

7.1.2 Asia Pacific oholic Steatohepatitis (NASH) Revenue by Countries (2013-2017)

7.1.3 China oholic Steatohepatitis (NASH) Market Status (2013-2017)

7.1.4 Japan oholic Steatohepatitis (NASH) Market Status (2013-2017)

7.1.5 India oholic Steatohepatitis (NASH) Market Status (2013-2017)

7.1.6 Southeast Asia oholic Steatohepatitis (NASH) Market Status (2013-2017)

7.1.7 Australia oholic Steatohepatitis (NASH) Market Status (2013-2017)

7.2 Asia Pacific oholic Steatohepatitis (NASH) Market Status by Manufacturers

7.3 Asia Pacific oholic Steatohepatitis (NASH) Market Status by Type (2013-2017)

7.3.1 Asia Pacific oholic Steatohepatitis (NASH) Sales by Type (2013-2017)

7.3.2 Asia Pacific oholic Steatohepatitis (NASH) Revenue by Type (2013-2017)

7.4 Asia Pacific oholic Steatohepatitis (NASH) Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

8.1 Latin America oholic Steatohepatitis (NASH) Market Status by Countries

8.1.1 Latin America oholic Steatohepatitis (NASH) Sales by Countries (2013-2017)

8.1.2 Latin America oholic Steatohepatitis (NASH) Revenue by Countries (2013-2017)

8.1.3 Brazil oholic Steatohepatitis (NASH) Market Status (2013-2017)

8.1.4 Argentina oholic Steatohepatitis (NASH) Market Status (2013-2017)

8.1.5 Colombia oholic Steatohepatitis (NASH) Market Status (2013-2017)

8.2 Latin America oholic Steatohepatitis (NASH) Market Status by Manufacturers

8.3 Latin America oholic Steatohepatitis (NASH) Market Status by Type (2013-2017)

8.3.1 Latin America oholic Steatohepatitis (NASH) Sales by Type (2013-2017)

8.3.2 Latin America oholic Steatohepatitis (NASH) Revenue by Type (2013-2017)

8.4 Latin America oholic Steatohepatitis (NASH) Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

9.1 Middle East and Africa oholic Steatohepatitis (NASH) Market Status by Countries

9.1.1 Middle East and Africa oholic Steatohepatitis (NASH) Sales by Countries (2013-2017)

9.1.2 Middle East and Africa oholic Steatohepatitis (NASH) Revenue by Countries (2013-2017)

9.1.3 Middle East oholic Steatohepatitis (NASH) Market Status (2013-2017)

9.1.4 Africa oholic Steatohepatitis (NASH) Market Status (2013-2017)

9.2 Middle East and Africa oholic Steatohepatitis (NASH) Market Status by Manufacturers

9.3 Middle East and Africa oholic Steatohepatitis (NASH) Market Status by Type (2013-2017)

9.3.1 Middle East and Africa oholic Steatohepatitis (NASH) Sales by Type (2013-2017)

9.3.2 Middle East and Africa oholic Steatohepatitis (NASH) Revenue by Type (2013-2017)

9.4 Middle East and Africa oholic Steatohepatitis (NASH) Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

10.1 Global Economy Situation and Trend Overview

10.2 oholic Steatohepatitis (NASH) Downstream Industry Situation and Trend Overview

CHAPTER 11 OHOLIC STEATOHEPATITIS (NASH) MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

11.1 Production Volume of oholic Steatohepatitis (NASH) by Major Manufacturers

11.2 Production Value of oholic Steatohepatitis (NASH) by Major Manufacturers

11.3 Basic Information of oholic Steatohepatitis (NASH) by Major Manufacturers

11.3.1 Headquarters Location and Established Time of oholic Steatohepatitis (NASH) Major Manufacturer

11.3.2 Employees and Revenue Level of oholic Steatohepatitis (NASH) Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

CHAPTER 12 OHOLIC STEATOHEPATITIS (NASH) MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Boehringer Ingelheim

12.1.1 Company profile

12.1.2 Representative oholic Steatohepatitis (NASH) Product

12.1.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim

12.2 Cerenis Therapeutics

12.2.1 Company profile

12.2.2 Representative oholic Steatohepatitis (NASH) Product

12.2.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Cerenis Therapeutics

12.3 Connexios Life Sciences

12.3.1 Company profile

12.3.2 Representative oholic Steatohepatitis (NASH) Product

12.3.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Connexios Life Sciences

12.4 Genfit

12.4.1 Company profile

12.4.2 Representative oholic Steatohepatitis (NASH) Product

12.4.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Genfit

12.5 Islet Sciences

12.5.1 Company profile

12.5.2 Representative oholic Steatohepatitis (NASH) Product

12.5.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Islet Sciences

12.6 Nimbus Therapeutics

12.6.1 Company profile

12.6.2 Representative oholic Steatohepatitis (NASH) Product

12.6.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Nimbus Therapeutics

12.7 Verva Pharmaceuticals

12.7.1 Company profile

12.7.2 Representative oholic Steatohepatitis (NASH) Product

12.7.3 oholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Verva Pharmaceuticals

12.8 Viking Therapeutics

- 12.8.1 Company profile
- 12.8.2 Representative cholic Steatohepatitis (NASH) Product
- 12.8.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Viking Therapeutics
- 12.9 Astazeneca Plc
 - 12.9.1 Company profile
 - 12.9.2 Representative cholic Steatohepatitis (NASH) Product
 - 12.9.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Astazeneca Plc
- 12.10 Galmed Pharmaceuticals Ltd.
 - 12.10.1 Company profile
 - 12.10.2 Representative cholic Steatohepatitis (NASH) Product
 - 12.10.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Galmed Pharmaceuticals Ltd.
- 12.11 GENFIT SA
 - 12.11.1 Company profile
 - 12.11.2 Representative cholic Steatohepatitis (NASH) Product
 - 12.11.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of GENFIT SA
- 12.12 Gilead Science
 - 12.12.1 Company profile
 - 12.12.2 Representative cholic Steatohepatitis (NASH) Product
 - 12.12.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Gilead Science
- 12.13 Novo Nordisk
 - 12.13.1 Company profile
 - 12.13.2 Representative cholic Steatohepatitis (NASH) Product
 - 12.13.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Novo Nordisk
- 12.14 Immuron Ltd
 - 12.14.1 Company profile
 - 12.14.2 Representative cholic Steatohepatitis (NASH) Product
 - 12.14.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Immuron Ltd
- 12.15 Intercepts Pharmaceuticals
 - 12.15.1 Company profile
 - 12.15.2 Representative cholic Steatohepatitis (NASH) Product
 - 12.15.3 cholic Steatohepatitis (NASH) Sales, Revenue, Price and Gross Margin of Intercepts Pharmaceuticals

12.16 Enzo Biochem, Inc

12.17 Tobira Therapeutics, Inc.

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

13.1 Industry Chain of oholic Steatohepatitis (NASH)

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF OHOLIC STEATOHEPATITIS (NASH)

14.1 Cost Structure Analysis of oholic Steatohepatitis (NASH)

14.2 Raw Materials Cost Analysis of oholic Steatohepatitis (NASH)

14.3 Labor Cost Analysis of oholic Steatohepatitis (NASH)

14.4 Manufacturing Expenses Analysis of oholic Steatohepatitis (NASH)

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference

I would like to order

Product name: oholic Steatohepatitis (NASH)-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/O4D8257C34CEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O4D8257C34CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

